Oral versus intravenous fluoropyrimidines for colorectal cancer

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will undertake comparisons of intravenous 5FU to oral fluoropyrimidines separately for (i) trials in patients undergoing neoadjuvant and/or adjuvant treatment for colorectal cancer who have have undergone curative-intent resection and for (ii) trials in patients with advanced or metastatic colorectal cancer.

Primary objectives:

(a) To compare the effect of intravenous 5FU chemotherapy and oral fluoropyrimidine chemotherapy on disease-free survival (DFS) in patients having neoadjuvant and/or adjuvant treatment who have undergone curative-intent resection for colorectal cancer.

(b) To compare the effect of intravenous 5-fluorouracil chemotherapy and oral fluoropyrimidine chemotherapy on progression-free survival (PFS) in patients with advanced or metastatic colorectal cancer.

Secondary objectives:

(a) To compare the OS and toxicities experienced by patients treated with intravenous 5FU chemotherapy and oral fluoropyrimidine chemotherapy in the neoadjuvant and/or adjuvant setting for colorectal cancer, who have undergone curative-intent resection.

(b) To compare the OS and toxicities experienced by patients treated with intravenous 5FU chemotherapy and oral fluoropyrimidine chemotherapy for advanced or metastatic colorectal cancer.

(c) To compare the response rates in patients treated with intravenous 5FU chemotherapy and oral fluoropyrimidine chemotherapy for advanced or metastatic colorectal cancer.